let's be realistic..., page-3

I agree.

If you believe that the market will become competitive (say, more than 4 players including Apotex, Apicore, Reddy's and GSK....), then Reddy's will have to buy out the ACL Fonda business IMHO. Otherwise, they essentially face a much higher COGS and lower final margin (on total sales) than competitors.

Reddy's are not at all interested in the Oncology business (IMHO), which I suspect they have discussed with ACL as part of a longer term strategy (again IMHO).

I hope this takes a longer, rather than shorter time to play out as it is pretty likely that IMHO the Fonda market will grow faster than current market expectations as scripts are redirected from Lovenox etc to Fonda now that the price differential has begun to normalise.